The two drug-discovery projects for novel, next generation, innovative, patentable psychedelic compounds, are expected to expand Clearmind’s IP portfolio Tel Aviv, Israel / Vancouver, Canada, Jan. 19, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived…


Previous articleBexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™
Next articlePsychedelics Weekly – Client Data Concerns in Oregon, Hopeful Legalization in New Hampshire, and Vital & The Five Elements